Table 2.

General characteristics of the studies included.

First author of study	Study period	Study design	OAC alone (n = no. of patients)	OAC + APT (n = no. of patients)	Type of OAC	Type of SAPT	Definition of MACE	Definition of Bleeding	Definition of stroke	Mean age (yrs)	Male	Type of stents	Follow up duration
Lamberts (2014) (aspirin)	2002–2011	Observational registry	950	1471	VKA	Aspirin	MI/coronary death	ISTH major	Ischemic + systemic thromboembolism	73.4	66.10%	NR	1 yr
Lamberts (2014) (clopidogrel)	2002–2011	Observational registry	950	322	VKA	Clopidogrel	MI/coronary death	ISTH major	Ischemic + systemic thromboembolism	73	64.20%	NR	1 yr
Hamon (2014)	2010–2011	Prospective cohort	119	342	VKA	Aspirin or clopidogrel	Cardiovascular death/MI/non-hemorrhagic stroke	BARC≥3	Not reported	66.9	77.8	BMS or DES	2 yrs
Lemesle (2017)	2003–2004	Prospective cohort	1481	866	VKA	Aspirin or clopidogrel	Cardiovascular death/MI/stroke	Requiring hospitalization/transfusion	Not reported	73.2	71.20%	NR	4 yrs
Fischer (2018)	2010–2015	Observational registry	172	434	VKA or DOAC	Aspirin or clopidogrel	Cardiovascular death/MI/ischemic stroke	TIMI bleeding requiring medical attention	Not reported	76	68.90%	BMS or DES	2.8 yrs
Patti (2018)	2012–2016	Observational registry	710	348	VKA or DOAC	Aspirin or clopidogrel	Acute coronary syndrome	ISTH major	Not reported	74.1	78.60%	BMS or DES	1 yr
Matsumura-Nakano (2018)	2013–2016	Randomized control trial	344	346	VKA or DOAC	Aspirin or clopidogrel	Cardiovascular death/MI/ischemic stroke/systemic embolism	ISTH major	Stroke or systemic embolism	75.1	85.20%	BMS or DES	2.5 yrs
Yasuda (2019)	2015–2017	Randomized control trial	1107	1108	DOAC	Aspirin or P2Y12	Cardiovascular and non- cardiovascular death/MI/ischemic stroke/systemic embolism	ISTH major	Ischemic + systemic thromboembolism	74.3	79.00%	BMS or DES	23 mos